Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
November 29, 2004
- Semi-annual Business Results
November 29, 2004
- Semi-annual Business Results
November 29, 2004
- Semi-annual Business Results
November 29, 2004
- Semi-annual Business Results
November 29, 2004
- Towa Lowers Sales Forecast for Products Listed in July by 50%
November 22, 2004
- WORLD NEWS IN BRIEF
November 22, 2004
- CAGR of 7% in Sales, 15% in Operating Profits over 3 Years Targeted: Astellas
November 22, 2004
- Kenei: Net Profits Decline Due to Contract Mfg Slump
November 22, 2004
- Sales Goal of Spiriva Set for \20 Bil.: NBI, Pfizer
November 22, 2004
- Shionogi to Make All-out Effort to Boost Sales of Crestor
November 22, 2004
- FPMAJ, JPMA Submit Petition on FY2005 Budget, Tax Reform
November 22, 2004
- Yamanouchi: Focusing on Rx Drugs Prior to Merger
November 22, 2004
- BUSINESS NEWS IN BRIEF
November 22, 2004
- Kyorin: Profits Down Due to Increase in R&D Spending in Full Year
November 22, 2004
- Sosei Aims at Sales of \21 Bil. in 2010
November 22, 2004
- Ono to Consider Independent Marketing Overseas Later: Mr Matsumoto
November 22, 2004
- Korosho Panel Tackles Problems of Off-Label Use of Drugs
November 22, 2004
- Kyorin: Overseas Sales Make Up for Domestic Slump
November 22, 2004
- REGULATORY NEWS IN BRIEF
November 22, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…